Glaukos

Glaukos EBIT per Employee

The EBIT per Employee of Glaukos (GKOS) as of Oct 29, 2026 is -79,280.62 USD. In the previous year, EBIT per Employee was -111,851.92 USD — a change of -29.12% (higher).

EBIT per Employee

-79,280.62USD

YoY

-29.12%

Last updated:

EBIT per Employee of Glaukos is 2025 -79,280.62 USD. EBIT per Employee of Glaukos was 2024 -111,851.92 USD. It decreases by -29.12% higher compared to the previous year.

The Glaukos EBIT per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT per Employee
Date
EBIT per Employee
Jan 1, 2018
-11,884.83 USD
Jan 1, 2019
-45,970.75 USD
Jan 1, 2020
-110,217.55 USD
Jan 1, 2021
-33,988.12 USD
Jan 1, 2022
-79,601.46 USD
Jan 1, 2023
-118,151.74 USD
Jan 1, 2024
-111,851.92 USD
Jan 1, 2025
-79,280.62 USD
The Glaukos EBIT per Employee history
YEAREBIT per EmployeeYoY
-79,280.62USD-29.12%
-111,851.92USD-5.33%
-118,151.74USD+48.43%
-79,601.46USD+134.20%
-33,988.12USD-69.16%
-110,217.55USD+139.76%
-45,970.75USD+286.80%
-11,884.83USD+470.01%
-2,085.01USD-153.78%
3,876.60USD-141.19%
-9,411.33USD-21.83%
-12,039.31USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Glaukos Stock analysis

What does Glaukos do? Glaukos Corp is a medical technology company specializing in developing devices and therapies for treating eye diseases. It was founded in 1998 by employees of the ophthalmology center at the University of California San Francisco. The company focuses on utilizing new technologies and therapies to improve the vision quality of patients. They have developed innovative products for diagnosing and treating various eye conditions, including glaucoma. Their core business involves manufacturing and distributing medical devices for glaucoma treatment, such as the iStent implant. They have also partnered with other institutions to advance research and development in the field of ophthalmology. In 2018, Glaukos Corp acquired the German manufacturer Markt II Medical, expanding their product offerings for a wider range of eye diseases. In summary, Glaukos Corp is an innovative medical technology company that aims to enhance patients' vision quality while minimizing the risks of eye surgery. Glaukos is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Glaukos stock

EBIT per Employee of Glaukos is -79,280.62 USD in 2025.

EBIT per Employee of Glaukos changed from -111,851.92 USD to -79,280.62 USD, representing a -29.12% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBIT per Employee Glaukos since 2006 – with annual values, charts, and detailed analysis.

EBIT per employee measures operating profit per employee, showing how efficiently the workforce generates operating earnings.

EBIT per Employee's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBIT per Employee's Glaukos historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — Glaukos

All Key Metrics — Glaukos